NCT01695330View on ClinicalTrials.gov

Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Multiple Myeloma
Interventions
DRUG

Subcutaneous bortezomib

Bortezomib will be administered SC at a dose of 1.0 mg/m2. Doses are to be administered on days 1, 4, 8, and 11 of a 28-day cycle. All other drugs used in combination with the SC bortezomib as well as their doses and schedules will be at the discretion of the Principal Investigator.

Trial Locations (1)

90069

James R. berenson, M.D., Inc., West Hollywood

Sponsors

Lead Sponsor

Oncotherapeutics
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Oncotherapeutics

INDUSTRY

NCT01695330 - Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens | Biotech Hunter | Biotech Hunter